2 Chinese pharmaceutical companies on the Fortune 500 list.

On August 10, a new round of Fortune 500 companies announced that this year's Fortune 500 companies reached a record $33 trillion in operating income.
the threshold for entering the rankings has also been raised from $24.8 billion to $25.4 billion.
this year, 133 Chinese companies are on the 2020 Fortune 500 list, with Sinopec still in second place and State Grid in third place.
Another author combed found that this time a total of 21 pharmaceutical companies in the world, including two Chinese pharmaceutical companies, respectively, China Pharmaceutical Group and Shanghai Pharmaceutical Group, and Shanghai Pharmaceutical Group as the new list of Chinese companies.
China Pharmaceutical Group Ranking: 145 Revenue: 70689.5 million U.S. dollars Compared with the previous year, China Pharmaceutical Group (hereinafter referred to as "National Pharmaceutical Group") jumped 24 places.
data show that The State Pharmaceutical Group is the leading state-owned enterprises in the domestic pharmaceutical industry, with more than 1500 subsidiaries and State Pharmaceutical Holdings, China Pharmaceuticals, National Pharmaceuticals, Tiantan Bio, Modern Pharmaceuticals, China Traditional Medicine 6 listed companies, the total number of employees of 150,000 people.
2019, China National Pharmaceutical Group's operating income of nearly 500 billion yuan, ranked 169th in the list of the world's top 500 enterprises, in the world's top 500 pharmaceutical companies in the list of the top 5.
recently, it was reported that the Chinese Pharmaceutical Group China Bio-Beijing Biological Products Research Institute of the new crown inactivated vaccine production workshop through the relevant departments of the state organized by the joint biosecurity inspection, with conditions for use.
, the production facility has obtained a new crown vaccine production license.
pharmaceutical group said the completion of the new crown inactivated vaccine production workshop, filling the gap in the domestic hardware infrastructure.
the same time, with the relevant departments to prepare the first vaccine bio-safety production facilities standards and biosecurity system documents, to fill The human vaccine high-grade biosecurity workshop hardware standards and management system gaps.
of the workshop provides a safe and reliable hardware guarantee for the current mass production of vaccines and for ensuring the efficiency and production capacity of vaccine research and development in the event of a possible future outbreak of a major infectious disease.
Pharmaceutical Group ranking: 473 revenue: 27005.4 million U.S. dollars as a new list of pharmaceutical companies, Shanghai Pharmaceutical Group has also received industry attention.
information, Shanghai Pharma is a leading pharmaceutical company covering pharmaceutical manufacturing and commerce, which was listed on the Main Board of the Hong Kong Stock Exchange in 2011 and raised about HK$15.5 billion.
It is learned that in the 11 years since the restructuring, Shanghai Pharma has accelerated market-oriented reform through endo-life growth and foreign mergers and acquisitions cooperation, and the company's overall strength has achieved leapfrog development, with a business scale growth of nearly 7 times (an average annual compound growth rate of nearly 20%), a fourfold increase in net profit, a fourfold increase in net assets and a threefold increase in market value.
's 2019 annual report shows that revenue reached RMB186.566 billion, up 17.27% YoY, of which the pharmaceutical industry achieved sales revenue of RMB23.490 billion, up 20.70% YoY, and grew by more than 20% for 11 consecutive quarters, entering the 48th place among the top 50 industries in the world.
In terms of product line, Shanghai Pharma has a rich product line, year-on-year production of about 700 drug types, covering cardiovascular, immunomodating, systemic anti-infection, blood and hematathmic organs and many other fields, sales of more than 100 million products reached 35 (over 500 million products up to 9).
pharmaceutical business directly covers 24 provinces in China, achieving sales revenue of 163,076 million yuan, ranking second in the national industry.
it is understood that Shanghai Medicine has started the construction of an international modern logistics center in the new area of Shanghai Free Trade Zone.
addition, Shanghai Pharma attaches great importance to research and development investment, in 2019 the number of pharmaceutical research and development personnel in Shanghai has exceeded 1200, research and development costs reached 1.350 billion yuan, an increase of 27.22% year-on-year, innovative drugs and generic drugs have made significant progress.
16 innovative drug products (17 adaptations) are in the clinical research and clinical trial application stage, and 13 generic drug varieties (16 products) have passed the consistency evaluation.
.